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Asthma 
'' Asthma is a disease characterized by an 
increased responsiveness of the trachea and 
bronchi to various stimuli and manifested by a 
widespread narrowing of the airways that 
changes in severity either spontaneously or in 
response to therapy." 1 The airway narrowing is 
the end result of some combination of bronchial 
muscle contraction, tissue inflammation , mu-
cosa! edema, and luminal occlusion by cellular 
debris and thickened secretions. During the last 
decade, basic and applied research has shed 
light on the physiology of the above changes 
and has led to breakthroughs in therapy and the 
more rational use of older and newer therapeu-
tic agents, both separately and together. 
Anatomy 
The nasal passages, the oropharynx, and 
the large , and some smaller, bronchi are exten-
sively provided with a variety of receptors which 
respond to temperature and irritating stimuli of 
many types. The sensory signals emanating 
from these receptors and others are transported 
to the central nervous system by the vagus 
nerve. The motor innervation of the bronchi is 
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via the vagus (cholinergic) and sympathetic 
trunks (adrenergic} , both of which affect bron-
chomotor tone and secretions. 
The epithelium of the intrathoracic airways 
is covered with a "mucociliary blanket" which 
facilitates the removal of particulate material ; 
mucus is secreted by glandular epithelial cells . 
Ciliated epithelium constantly moves the mucus 
layer from peripheral to central airways, where 
cough and expectoration eliminate the trapped 
particles from the respiratory tract. 
The multiple branching airways of the 
lung, as far distal as the respiratory bronchiole, 
are surrounded by bands of smooth muscle. 
Proportionately greater amounts of muscle are 
present in small bronchioles relative to large 
and medium bronchi , and constriction of this 
musculature can virtually occlude the airway. 
Physiology 
For any given flow rate, airways resistance 
is dependent on the cross-sectional area 
through which the gas is flowing, that is , the 
larger the cross-sectional area the less the resis-
tance and vice versa. Bronchial smooth muscle 
contraction can markedly increase resistance 
and this can be augmented by compromise of 
the airway 's lumen by secretions, cells, and 
other factors . Stimulation of the vagus nerve in-
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duces bronchial smooth muscle contraction and 
increases mucus secretion ; sympathetic nerve 
stimulation has a minimal opposite effect. 
The relative "tone " of bronchial smooth 
muscle, that is, the balance between muscle 
contraction and relaxation , is controlled by the 
intracellular ratio of the cyclic nucleotides. High 
levels of cyclic adenosine monophosphate 
(cAMP), induce relaxation, and conversely, in-
creased levels of cycl ic guanosine mono-
phosphate (cGMP), induce contraction . Beta 
agonists (isoproterenol, ephedrine, terbutaline, 
among other drugs) appear to increase levels of 
cAMP by stimulation of the enzyme adenylcy-
clase; corticosteroids may work in this fashion 
as well. Methylxanthines, such as theophylline, 
appear to prevent the breakdown of cAMP by 
the enzyme phosphodiesterase and thus in-
crease intracellular cAMP levels. Vagal stimula-
tion in turn stimulates cAMP production, caus-
ing bronchoconstriction . 2 
Pathophysiology 
A large population of mast cells contain-
ing a variety of preformed "mediators" of hy-
persensitivity such as histamine are normally 
found in the pulmonary interstitium; these cells 
can synthesize from precursors other mediators 
such as a slow-reacting substance of ananphy-
laxis (SRS-A). Both of these substances are 
powerful bronchoconstrictors and may increase 
cell membrane permeability, leading to mucosa! 
edema. Additionally, these mediators increase 
bronchial receptor sensitivity thus enhancing 
neurogenic-induced bronchoconstriction. Other 
mediators can cause inflammatory changes in 
bronchi and attract and activate phagocytic 
cells . 
In extrinsic (allergic) asthma, mast cells 
are sensitized by the attachment of antigen-spe-
cific lgE to their surface. If an appropriate anti-
gen, such as pollen, fixes to the lgE, the various 
mediators are released and/ or synthesized. 3 
The rate of release/synthesis of mediators is 
governed by the cAMP /cGMP ratio in the mast 
I 
cell , and is thus subject to pharmacologic ma-
nipulation as has been discussed. 
In other types of asthma (adult onset, in-
trinsic, aspirin-induced , and other forms) immu-
nologic mechanisms do not play a dominant 
role. Some suggested mechanisms causing the 
airway hyperreactivity in these types of asthma 
are: 
B-adrenergic blockade: A decreased re-
sponse to beta agonist drugs has been noted 
in many asthmatics. It is possible that either 
congenital defects in adenylcyclase production 
or recurrent infections could induce this block-
ade. 
Cholinergic dominance: This hypothesis 
presupposes that the vagus nerve in the asth-
matic is easily stimulated via the irritant recep-
tors, leading to an enhanced bronchoconstric-
tive response (the ''twitchy vagus '' theory). 
Cortical (emotional) components may act via 
this pathway. Whether the vagus hyperreactivity 
is a primary or secondary defect is in question . 
Histamine, for example, increases irritant-recep-
tor sensitivity and indirectly plays a role in va-
gally mediated bronchoconstriction . 
Adrenergic amine deficiency: This hypoth-
esis presupposes that in response to broncho-
constrictive stimul i, the adrenal medulla should 
release additional epinephrine to partially mod-
ify this response (epinephrine acting as a beta 
agonist) . In the asthmatic , this response is im-
paired . 
Smooth muscle abnormalities: Asthmatics 
are known to have hypertrophied bronchial 
musculature. Whether or not the muscle is also 
innately more reactive is undecided . 
Alpha-adrenergic hyperresponsiveness: 
Some asthmatics have been shown to have an 
exaggerated response to phenylephrine (a pure 
alpha agonist) in organs other than the lung. It is 
thus hypothesized that naturally occurring alpha 
agonists (which increase mast cell and bron-
chial musculature intracellular cGMP) can in-
duce bronchoconstriction . 
Much is still to be learned about asthma. 
Apparently, in all individuals, many factors play 
a role in the pathogenesis of the disease, some 
factors being dominant and others seeming less 
significant. It is the clinician's responsibility to 
determine in his patient which factors pre-
dominate and to tailor the treatment to these 
findings. 
Chronic Obstructive Pulmonary Disease 
(COPD} 
Emphysema and bronchitis constitute the 
major disease entities which fall under the head-
ing of Chronic Obstructive Pulmonary Disease 
(COPD). Although emphysema and bronchitis 
will , for discussion purposes, be considered 
separately , they occur concomitantly in most 
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patients with COPD. Only a small percentage of 
patients will have ''pure'' emphysema or 
" pure" bronchitis. 
"Class.ic" Findings in Far-Advanced Em-
physema and Bronchitis 
Emphysema is defined as destruction of 
terminal alveolar capillary units with enlarge-
ment of the remaining air spaces. Etiologically, 
it is causally related to cigarette smoking and 
certain genetic disorders such as alpha 1 anti-
trypsin deficiency. In addition , there is some evi-
dence that recurrent childhood pulmonary in-
fections predispose smokers to emphysema. 
The typical patient with far-advanced em-
physema is 45 to 50 years of age and com-
plains of dyspnea on mild exertion . Unless an 
associated bronchitis is present, cough and 
sputum production do not occur. Physical ex-
amination reveals a thin, cachectic patient with 
an increased respiratory rate , using his or her 
accessory muscles of respiration, an increase in 
anteroposterior chest diameter, a tympanitic 
chest percussion note, and decreased breath 
sounds. Laboratory results are unremarkable 
and the chest radiograph shows a vertical, 
small heart with clear , hyperinflated lung fields; 
· the EKG shows low voltage. Pulmonary function 
tests are consistent with hyperinflation, de-
creased flow rates and diffusing capacity and 
airway collapse . Mild hypoxemia (Pa02 > 55 
torr) and normocapnea (PaC02 < 45 torr) are 
common findings . Because of the labored 
breathing and lack of cyanosis this type of pa-
tient has been termed the " pink puffer." As 
lung destruction is the basic problem, most 
therapeutic interventions are nonrewarding, but 
teaching the patient to purse-lip breathe may 
lessen the dyspnea and decrease the respira-
tory rate. 1 
Chronic bronchitis is defined as an in-
crease in sputum production two to three 
months out of the year for two years in a row. 
Patients with this condition usually are cigarette 
smokers and/or have been exposed to indus-
trial or air pollutants. Their chief complaint is a 
cough productive of sputum , often described as 
"a cigarette or morning cough ." The bronchitic 
patient shows no evidence of weight loss , has a 
normal chest AP diameter but may have, on 
auscultation , wheezes, rhonchi , and early in-
spiratory rales . In addition, signs of right ven-
tricular failure (jugular venous distention, hepa-
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Fig-Decreases in FEV 1 with age in nonsmokers, non-
susceptible smokers and susceptible smokers. This graph 
depicts fall in FEV 1 in one particular susceptible smoker. 
Other smokers will have different FEV 1 loss rates thus 
reaching the " disability" line at different ages. See text for 
explanation <i!nd discussion . 
tomegaly, and peripheral edema) may be 
present. Polycythemia and, in certain cases, ei-
ther sputum or blood eosinophilia may be found 
on routine laboratory analysis. Carbon dioxide 
retention (PaC0 2 > 45 torr) and hypoxemia 
(Pa02 < 55 torr) are found on arterial blood gas 
analysis; pulmonary function tests reveal de-
creased flow rates which may respond to 
bronchodilators. Chest radiography shows an 
enlarged heart (mainly right ventricle) with in-
creased bibasilar lung markings; the EKG may 
show right ventricular hypertrophy. Because of 
the cyanosis and the peripheral edema, these 
patients have been termed "blue bloaters." 
Treatment consists of antibiotics for recurrent 
pulmonary infections, diuretics and digitalis for 
the right heart failure and supplemental oxygen 
for the hypoxemia. 
Which Patients are at Risk of Developing 
Symptomatic COPD? 
The patient with far-advanced COPD re-
sponds poorly to treatment and the average life 
expectancy after severe symptoms ensue is 
3 % to 5 years. 2 It would be advantageous to 
predict which patients who smoke may develop 
far-advanced disease as it is now known that · 
90% to 95% of all smokers are either not sus-
ceptible or minimally susceptible to the effect of 
cigarette smoke; that is, life-long smoking does 
not lead to symptomatic lung disease as de-
scribed above. Most cigarette smokers have 
normal or near normal FEV 1s compared to age-
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matched nonsmoking controls (Line A, Figure). 3 
A small percentage of patients, however, may 
be susceptible to cigarette smoke and if FEV 1 s 
are performed yearly (after age 40), there will 
be a marked decline in the FEV, per year (Line 
B, Figure) compared to normal values (Line A, 
Figure). If these patients continue to smoke, 
they will become symptomatic and disabled at a 
relatively early age; if they stop smoking, the 
FEV, decline will slow (Line C, Figure), but im-
paired pulmonary functions may be demon-
strable, although the patient may be asympto-
matic. If smoking is stopped late in the course 
of the disease (that is, by the time disability oc-
curs), although the FEV1 decline will improve, 
death will ensue in a relatively short period of 
time (Line D, Figure). Therefore, FEV 1s should 
be performed yearly in all cigarette smokers > 
40 years of age. If a marked loss of FEV1 oc-
curs (> 60 to 70cc/sec/yr), an aggressive ap-
proach to cessation of smoking should be insti-
tuted. 
The Figure is modified by permission from the British 
Medical Journal ,(1 : 1645-1648, 1977). 
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